China’s burgeoning biotechnology sector is reshaping the global pharmaceutical pipeline, with increased government support leading to a surge in innovative drug development. Over the past decade, China has established an ecosystem of biotech firms that are now producing a diverse array of drug candidates, often at lower costs and with greater regulatory flexibility than their U.S. counterparts. In 2025, one-third of the pharmaceutical industry’s licensing spending involved drugs from China, highlighting the growing interest of large pharma and venture capitalists in these experimental medicines. The latest trends indicate a particular focus on bispecific and trispecific drugs for cancer and immune diseases, primarily involving early-stage candidates.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biopharmadive.com/news/china-biotech-drug-licensing-deals-pipeline/758283/
